News stories about NeuroMetrix (NASDAQ:NURO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NeuroMetrix earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the medical device company an impact score of 44.9563779374953 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective (down from $10.00) on shares of NeuroMetrix in a research note on Friday, October 20th.
Shares of NeuroMetrix (NURO) opened at $1.82 on Tuesday. NeuroMetrix has a 12 month low of $1.58 and a 12 month high of $11.04.
NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.
Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.